The attached link to the EXPLOITATION phase of the NILVAD STUDY details the effort facing Dr. Mullan and his team once the study results are released. As I have seen elsewhere, the plan is to submit the study results to a proper publication (I hope the New England Journal of Medicine), for peer review and publication. The better the publication, the more impact the results will have.
Positive study results, which Dr. Mullan seems to be signaling would put Archer ahead of the pack with enough of a lead that it will be very difficult for others to catch up, unless someone comes up with a presently unexpected breakthrough. Those who want to board the nilvadipine gravy train will have to get in line and make their bid!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.